Bryan M. Reasons
CIK 1553489 · EVP & CFO · last filed 2025-08-04
Bryan M. Reasons is an EVP & CFO who has filed 57 SEC Form 4 insider transactions across 6 companies since 2013. Across all open-market trades the lifetime net is −$204.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions. 15 SEC filings were submitted jointly with Recro Pharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
30831 HUNTWOOD AVENUE
HAYWARD, CA 94544
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACRS | Director | 28,732 | $3.79 | $108.9K | $0 | 8 | 2024-06-04 |
| Societal CDMO, Inc. (SCTL) Delisted | Director | 0 | $1.10 | $0 | $25.0K | 4 | 2024-04-08 |
| Keenova Therapeutics plc (MNK) Delisted | EVP & CFO | 96,660 | $0.34 | $32.9K | $47.5K | 9 | 2023-08-18 |
| Societal CDMO, Inc. (REPH) Delisted | Director | 67,429 | $2.09 | $140.9K | $0 | 10 | 2021-05-17 |
| AMRX | CFO | 82,986 | $21.02 | $1.74M | -$276.7K | 2 | 2018-08-23 |
| Impax Laboratories, LLC (IPXL) Delisted | Chief Financial Officer | 94,684 | — | — | $0 | 19 | 2018-03-05 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-04 | — | Grant (A) | — | $0 | |
| 2025-01-02 | — | Mixed | +5,114 | $0 | |
| 2024-06-04 | ACRS | Exer (M) | +4,660 | $0 | EDGAR |
| 2024-04-08 | Societal CDMO, Inc. (SCTL) Delisted | Mixed | −291,049 | -$320.2K | EDGAR |
| 2024-02-06 | — | Grant (A) | — | $0 | |
| 2023-11-16 | — | Disp (D) | −96,660 | $0 | |
| 2023-08-28 | Societal CDMO, Inc. (SCTL) Delisted | Buy (P) | +62,500 | $25.0K | EDGAR |
| 2023-08-18 | Keenova Therapeutics plc (MNK) Delisted | Tax (F) | −15,976 | -$11.1K | EDGAR |
| 2023-07-05 | Keenova Therapeutics plc (MNK) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-06-05 | ACRS | Mixed | +4,507 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.